Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
about
Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@ast
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@en
type
label
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@ast
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@en
prefLabel
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@ast
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@en
P2093
P2860
P1433
P1476
Adjuvant Trastuzumab in HER2-P ...... atus: A Cost-Utility Analysis.
@en
P2093
Giorgi Kvizhinadze
Nisha Nair
William Leung
P2860
P304
P356
10.1371/JOURNAL.PMED.1002067
P407
P50
P577
2016-08-09T00:00:00Z